These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 30900478)

  • 1. Stiripentol for the treatment of seizures associated with Dravet syndrome.
    Chiron C
    Expert Rev Neurother; 2019 Apr; 19(4):301-310. PubMed ID: 30900478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stiripentol for the treatment of seizures in Dravet syndrome.
    Eschbach K; Knupp KG
    Expert Rev Clin Pharmacol; 2019 May; 12(5):379-388. PubMed ID: 31017478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis.
    Guerrini R; Chiron C; Vandame D; Linley W; Toward T
    Epilepsia Open; 2024 Apr; 9(2):689-703. PubMed ID: 38427284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Lattanzi S; Trinka E; Russo E; Del Giovane C; Matricardi S; Meletti S; Striano P; Damavandi PT; Silvestrini M; Brigo F
    Drugs; 2023 Oct; 83(15):1409-1424. PubMed ID: 37695433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stiripentol: A Novel Antiseizure Medication for the Management of Dravet Syndrome.
    Buck ML; Goodkin HP
    Ann Pharmacother; 2019 Nov; 53(11):1136-1144. PubMed ID: 31167540
    [No Abstract]   [Full Text] [Related]  

  • 6. Dravet syndrome: Treatment options and management of prolonged seizures.
    Cross JH; Caraballo RH; Nabbout R; Vigevano F; Guerrini R; Lagae L
    Epilepsia; 2019 Dec; 60 Suppl 3():S39-S48. PubMed ID: 31904119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A critical evaluation of fenfluramine hydrochloride for the treatment of Dravet syndrome.
    Schoonjans AS; Ceulemans B
    Expert Rev Neurother; 2022 May; 22(5):351-364. PubMed ID: 33455486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative short-term efficacy and safety of add-on anti-seizure medications in Dravet syndrome: An indirect treatment comparison.
    Devi N; Madaan P; Asrar MM; Sahu JK; Bansal D
    Seizure; 2021 Oct; 91():316-324. PubMed ID: 34274891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial.
    Nabbout R; Mistry A; Zuberi S; Villeneuve N; Gil-Nagel A; Sanchez-Carpintero R; Stephani U; Laux L; Wirrell E; Knupp K; Chiron C; Farfel G; Galer BS; Morrison G; Lock M; Agarwal A; Auvin S;
    JAMA Neurol; 2020 Mar; 77(3):300-308. PubMed ID: 31790543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stiripentol: A Review in Dravet Syndrome.
    Frampton JE
    Drugs; 2019 Nov; 79(16):1785-1796. PubMed ID: 31617141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Stiripentol and the Clinical Outcome in Dravet Syndrome.
    Yıldız EP; Ozkan MU; Uzunhan TA; Bektaş G; Tatlı B; Aydınlı N; Çalışkan M; Özmen M
    J Child Neurol; 2019 Jan; 34(1):33-37. PubMed ID: 30362398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stiripentol in Dravet syndrome: results of a retrospective U.S. study.
    Wirrell EC; Laux L; Franz DN; Sullivan J; Saneto RP; Morse RP; Devinsky O; Chugani H; Hernandez A; Hamiwka L; Mikati MA; Valencia I; Le Guern ME; Chancharme L; de Menezes MS
    Epilepsia; 2013 Sep; 54(9):1595-604. PubMed ID: 23848835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stiripentol for the treatment of seizures associated with Dravet syndrome in patients 6 months and older and taking clobazam.
    Vasquez A; Wirrell EC; Youssef PE
    Expert Rev Neurother; 2023 Apr; 23(4):297-309. PubMed ID: 36975187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do children with Dravet syndrome continue to benefit from stiripentol for long through adulthood?
    Chiron C; Helias M; Kaminska A; Laroche C; de Toffol B; Dulac O; Nabbout R; An I
    Epilepsia; 2018 Sep; 59(9):1705-1717. PubMed ID: 30132836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety and efficacy of stiripentol for the treatment of Dravet syndrome: A multicenter, open-label study in Japan.
    Inoue Y; Ohtsuka Y;
    Epilepsy Res; 2015 Jul; 113():90-7. PubMed ID: 25986195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stiripentol and vigabatrin current roles in the treatment of epilepsy.
    Chiron C
    Expert Opin Pharmacother; 2016 Jun; 17(8):1091-101. PubMed ID: 26933940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current therapeutic procedures in Dravet syndrome.
    Chiron C
    Dev Med Child Neurol; 2011 Apr; 53 Suppl 2():16-8. PubMed ID: 21504427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic advances in Dravet syndrome: a targeted literature review.
    Strzelczyk A; Schubert-Bast S
    Expert Rev Neurother; 2020 Oct; 20(10):1065-1079. PubMed ID: 32799683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of CYP2C19 Phenotypes on Clinical Efficacy of Stiripentol in Japanese Patients With Dravet Syndrome.
    Yamamoto Y; Takahashi Y; Ikeda H; Imai K; Kagawa Y; Inoue Y
    Ther Drug Monit; 2020 Apr; 42(2):302-308. PubMed ID: 31318844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dravet Syndrome: A Review of Current Management.
    Wheless JW; Fulton SP; Mudigoudar BD
    Pediatr Neurol; 2020 Jun; 107():28-40. PubMed ID: 32165031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.